[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Ott PA, Hamilton A, Jones A, Haas N, Shore T, Liddell S, Christos PJ, Doyle LA, Millward M, Muggia FM, Pavlick AC: A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma. PLoS One; 2010 Jan 20;5(1):e8714
Hazardous Substances Data Bank. Ixabepilone .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Ixabepilone (BMS-247550), an epothilone B analog, is a microtubule stabilizing agent which has shown activity in several different tumor types and preclinical models in melanoma.
  • In an open label, one-arm, multi-center phase II trial the efficacy and toxicity of this epothilone was investigated in two different cohorts: chemotherapy-naïve (previously untreated) and previously treated patients with metastatic melanoma.
  • The primary endpoint was response rate (RR); secondary endpoints were time to progression (TTP) and toxicity.
  • One patient in the previously treated group developed neutropenia and fatal septic shock.
  • Median TTP was 1.74 months in the previously untreated group (95% CI = 1.51 months, upper limit not estimated) and 1.54 months in the previously treated group (95% CI = 1.15 months, 2.72 months).
  • CONCLUSIONS/SIGNIFICANCE: Ixabepilone has no meaningful activity in either chemotherapy-naïve (previously untreated) or previously treated patients with metastatic melanoma.
  • Further investigation with ixabepilone as single agent in the treatment of melanoma is not warranted.
  • [MeSH-major] Epothilones / therapeutic use. Melanoma / drug therapy. Tubulin Modulators / therapeutic use
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Neuro Oncol. 2009 Apr;11(2):158-66 [18780814.001]
  • [Cites] Melanoma Res. 2004 Feb;14(1):63-6 [15091196.001]
  • [Cites] Ann Oncol. 2004 Jun;15(6):928-32 [15151950.001]
  • [Cites] Melanoma Res. 2004 Oct;14(5):415-20 [15457099.001]
  • [Cites] Cancer. 1990 Jun 1;65(11):2478-81 [1970948.001]
  • [Cites] Invest New Drugs. 1991 Feb;9(1):59-64 [1673965.001]
  • [Cites] Stat Med. 1994 Sep 15;13(17):1727-36 [7997706.001]
  • [Cites] Eur J Cancer. 1994;30A(8):1061-4 [7654429.001]
  • [Cites] J Clin Oncol. 1995 Dec;13(12):2895-9 [8523052.001]
  • [Cites] J Biol Chem. 1997 Jan 24;272(4):2534-41 [8999970.001]
  • [Cites] Med Oncol. 1996 Jun;13(2):111-7 [9013474.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1439-46 [15735119.001]
  • [Cites] Br J Cancer. 2005 Mar 28;92(6):1006-12 [15756276.001]
  • [Cites] Clin Cancer Res. 2005 Nov 1;11(21):7773-84 [16278399.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8724-9 [16314632.001]
  • [Cites] Invest New Drugs. 2006 Sep;24(5):441-6 [16586011.001]
  • [Cites] Cancer. 2007 Aug 15;110(4):759-63 [17594721.001]
  • [Cites] J Clin Oncol. 2007 Aug 10;25(23):3415-20 [17606972.001]
  • [Cites] J Clin Oncol. 2007 Aug 10;25(23):3448-55 [17606973.001]
  • [Cites] J Clin Oncol. 2007 Aug 10;25(23):3407-14 [17606974.001]
  • [Cites] Cancer Biol Ther. 2007 Apr;6(4):490-3 [17457044.001]
  • [Cites] J Clin Oncol. 2007 Nov 20;25(33):5210-7 [17968020.001]
  • [Cites] Ann Oncol. 2008 May;19(5):977-83 [18296423.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13157-62 [18755900.001]
  • [Cites] Ann Oncol. 2008 Dec;19(12):2048-52 [18644829.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Feb;63(3):417-25 [18446338.001]
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):526-34 [19075286.001]
  • [Cites] Biochim Biophys Acta. 2000 May 17;1470(3):M79-91 [10799747.001]
  • (PMID = 20098694.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00036764
  • [Grant] United States / NCI NIH HHS / CA / N01CM62204; United States / NCI NIH HHS / CA / U01 CA076642; United States / NCI NIH HHS / CA / 1U01 CA76642; United States / NCI NIH HHS / CM / N01-CM-62204
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Epothilones; 0 / Tubulin Modulators; K27005NP0A / ixabepilone
  • [Other-IDs] NLM/ PMC2808339
  •  go-up   go-down


2. Palmerini E, Staals EL, Alberghini M, Zanella L, Ferrari C, Benassi MS, Picci P, Mercuri M, Bacci G, Ferrari S: Synovial sarcoma: retrospective analysis of 250 patients treated at a single institution. Cancer; 2009 Jul 1;115(13):2988-98
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The optimal treatment for synovial sarcoma remains controversial.
  • Treatment, outcome, and prognostic factors in patients treated in a single institution were examined.
  • RESULTS: Characteristics of the 250 patients (128 female; 122 male) included: median age, 37 years (range, 7-83 years); 177 (71%) with tumors in the lower extremity, 40 (16%) with tumors in the upper extremity, and 33 with tumors in the trunk (13%); primary lesion size >5 cm in 121 patients (55%); and 204 (82%) patients with localized disease and 46 (18%) with metastatic disease at the time of presentation.
  • In patients with localized disease, radiotherapy was administered to 103 (50%) patients, and chemotherapy to 98 (48%).
  • Age, size, histology, and use of radiotherapy influence prognosis, whereas to the authors' knowledge, the role of adjuvant chemotherapy remains unproven.
  • [MeSH-major] Sarcoma, Synovial / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Arm. Disease-Free Survival. Female. Humans. Leg. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19452538.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. O'Donnell TM, Devitt AT, Kutty S, Fogarty EE: Recurrent congenital haemangiopericytoma in a child. J Bone Joint Surg Br; 2001 Mar;83(2):269-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A five-day-old boy was referred with a soft-tissue mass in his right upper arm.
  • After MRI and selective angiography, excision biopsy was carried out, but no adjuvant therapy was administered.
  • Congenital haemangiopericytoma is a rare cause of a soft-tissue mass in children.
  • The treatment is controversial, but most centres recommend the use of adjuvant chemotherapy, combined with complete excision.
  • We recommend treatment with doxorubicin.
  • [MeSH-major] Hemangiopericytoma / congenital. Soft Tissue Neoplasms / congenital
  • [MeSH-minor] Arm. Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Infant, Newborn. Male. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11284579.001).
  • [ISSN] 0301-620X
  • [Journal-full-title] The Journal of bone and joint surgery. British volume
  • [ISO-abbreviation] J Bone Joint Surg Br
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


Advertisement
4. Grunhagen DJ, de Wilt JH, Graveland WJ, van Geel AN, Eggermont AM: The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma. Cancer; 2006 Jan 1;106(1):156-62
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Both patients with soft tissue sarcoma (STS) and patients with melanoma have limited treatment possibilities once the tumor has metastasized systemically.
  • Isolated limb perfusion (ILP) has proven to be an excellent, local, limb-saving treatment option in patients with locally advanced extremity tumors.
  • In this study, the authors investigated the palliative value of the ILP procedure to avoid amputation in patients who had Stage IV STS and melanoma.
  • All patients underwent an ILP with TNF and melphalan of the upper limb (n = 4 patients) or the lower limb (n = 47 patients) with 26-140 mg melphalan and 2-4 mg TNF.
  • Limb salvage was achieved in 36 of 37 patients, with 1 patient undergoing amputation due to treatment toxicity.
  • CONCLUSIONS: TNF-based ILP is an excellent procedure that provided tumor control and limb salvage for the short survival of patients with metastasized, very bulky, limb-threatening tumors of the extremity.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Melanoma / drug therapy. Melphalan / therapeutic use. Palliative Care. Sarcoma / drug therapy. Tumor Necrosis Factor-alpha / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Amputation. Arm. Female. Humans. Leg. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Recombinant Proteins / administration & dosage. Recombinant Proteins / adverse effects. Recombinant Proteins / therapeutic use

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 16323177.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Recombinant Proteins; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down


5. Ma X, Guo Y, Pang Z, Wang B, Lu H, Gu YJ, Guo X: A randomized phase II study of CEOP with or without semustine as induction chemotherapy in patients with stage IE/IIE extranodal NK/T-cell lymphoma, nasal type in the upper aerodigestive tract. Radiother Oncol; 2009 Dec;93(3):492-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase II study of CEOP with or without semustine as induction chemotherapy in patients with stage IE/IIE extranodal NK/T-cell lymphoma, nasal type in the upper aerodigestive tract.
  • PURPOSE: In this randomized phase II study, we evaluated the efficacy of semustine added to CEOP regimen as induction chemotherapy in patients with stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type in the upper aerodigestive tract.
  • RESULTS: The overall response rate of induction chemotherapy was 57.9% in CEOP arm compared with 62.2% in CEOP plus semustine arm (P=0.71).
  • More effective treatment needs to be explored in patients with intermediate or high risk.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Extranodal NK-T-Cell / drug therapy. Nose Neoplasms / drug therapy. Semustine / administration & dosage
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Epirubicin / administration & dosage. Epirubicin / adverse effects. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Pharyngeal Neoplasms / drug therapy. Pharyngeal Neoplasms / radiotherapy. Prednisone / administration & dosage. Prednisone / adverse effects. Prognosis. Radiation Injuries. Survival Rate. Vincristine / administration & dosage. Vincristine / adverse effects. Young Adult

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. Semustine .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19782419.001).
  • [ISSN] 1879-0887
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
  • [Publication-country] Ireland
  • [Chemical-registry-number] 13909-09-6 / Semustine; 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CEOP protocol 1
  •  go-up   go-down


6. Lemery SJ, Zhang J, Rothmann MD, Yang J, Earp J, Zhao H, McDougal A, Pilaro A, Chiang R, Gootenberg JE, Keegan P, Pazdur R: U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin Cancer Res; 2010 Sep 1;16(17):4331-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
  • Food and Drug Administration (FDA) approval of ofatumumab (Arzerra, GlaxoSmithKline) for the treatment of patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab.
  • EXPERIMENTAL DESIGN: The FDA reviewed the results of a planned interim analysis of a single-arm trial, enrolling 154 patients with CLL refractory to fludarabine, and a supportive dose-finding, activity-estimating trial in 33 patients with CLL.
  • The most common adverse reactions in the primary efficacy study were neutropenia, pneumonia, pyrexia, cough, diarrhea, anemia, fatigue, dyspnea, rash, nausea, bronchitis, and upper respiratory tract infections.
  • CONCLUSIONS: On October 26, 2009, the FDA granted accelerated approval to ofatumumab for the treatment of patients with CLL refractory to fludarabine and alemtuzumab, on the basis of demonstration of durable tumor shrinkage.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Drug Approval / legislation & jurisprudence. Drug Resistance, Neoplasm / drug effects. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Antibodies, Neoplasm / therapeutic use. Antigens, CD20 / immunology. Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Fever / chemically induced. Humans. Multicenter Studies as Topic. Neutropenia / chemically induced. Pneumonia / chemically induced. Treatment Outcome. United States. United States Food and Drug Administration. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20601446.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 0 / ofatumumab; 3A189DH42V / alemtuzumab; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


7. Maeda A, Boku N, Fukutomi A, Kondo S, Kinoshita T, Nagino M, Uesaka K: Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01). Jpn J Clin Oncol; 2008 Mar;38(3):227-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01).
  • A randomized controlled trial has begun in Japan to compare orally administered S-1 with intravenous gemcitabine (GEM) as adjuvant chemotherapy for patients with curatively resected pancreatic cancer.
  • Each treatment arm includes 180 patients, providing an expected hazard ratio of 0.87 and an upper margin of 1.25 (two-sided alpha-error, 0.05; power, 0.8).
  • Follow-up abdominal computed tomography is repeated every three months during the first two years, then every six months for three years.
  • [MeSH-major] Carcinoma, Ductal / drug therapy. Deoxycytidine / analogs & derivatives. Oxonic Acid / therapeutic use. Pancreatic Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Administration, Oral. Adult. Antimetabolites, Antineoplastic / therapeutic use. Chemotherapy, Adjuvant. Disease-Free Survival. Drug Administration Schedule. Drug Combinations. Humans. Injections, Intravenous. Japan / epidemiology. Neoplasm Staging. Pancreatectomy. Prospective Studies. Quality of Life. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer 1.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18272475.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0W860991D6 / Deoxycytidine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


8. van der Meij BS, Langius JA, Smit EF, Spreeuwenberg MD, von Blomberg BM, Heijboer AC, Paul MA, van Leeuwen PA: Oral nutritional supplements containing (n-3) polyunsaturated fatty acids affect the nutritional status of patients with stage III non-small cell lung cancer during multimodality treatment. J Nutr; 2010 Oct;140(10):1774-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral nutritional supplements containing (n-3) polyunsaturated fatty acids affect the nutritional status of patients with stage III non-small cell lung cancer during multimodality treatment.
  • The objective of this study was to investigate the effects of an oral nutritional supplement containing (n-3) fatty acids on nutritional status and inflammatory markers in patients with non-small cell lung cancer (NSCLC) undergoing multimodality treatment.
  • EPA in plasma phospholipids, energy intake, resting energy expenditure (REE), body weight, fat free mass (FFM), mid-upper arm circumference (MUAC), and inflammatory markers were assessed.
  • In conclusion, a protein- and energy-dense oral nutritional supplement containing (n-3) fatty acids beneficially affects nutritional status during multimodality treatment in patients with NSCLC.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / therapy. Fatty Acids, Omega-3 / administration & dosage. Lung Neoplasms / therapy. Nutritional Status / drug effects
  • [MeSH-minor] Adult. Aged. Biomarkers / blood. Combined Modality Therapy. Dietary Proteins / administration & dosage. Dietary Supplements. Double-Blind Method. Eicosapentaenoic Acid / blood. Energy Intake. Energy Metabolism. Female. Humans. Inflammation / blood. Male. Middle Aged. Neoplasm Staging. Patient Compliance. Phospholipids / blood. Placebos

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20739445.001).
  • [ISSN] 1541-6100
  • [Journal-full-title] The Journal of nutrition
  • [ISO-abbreviation] J. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Dietary Proteins; 0 / Fatty Acids, Omega-3; 0 / Phospholipids; 0 / Placebos; AAN7QOV9EA / Eicosapentaenoic Acid
  •  go-up   go-down


9. Tokiya R, Imajo Y, Yoden E, Hiratsuka J, Kobatake M, Gyoten M, Imai S, Kajihara Y: A long-term survivor of leiomyosarcoma around the right side of the base of the skull: effective radiotherapy combined with intra-arterial chemotherapy. Int J Clin Oncol; 2002 Feb;7(1):57-61
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A long-term survivor of leiomyosarcoma around the right side of the base of the skull: effective radiotherapy combined with intra-arterial chemotherapy.
  • We report a rare case of a leiomyosarcoma that developed around the right side of the base of the skull in a 51-year-old woman.
  • The patient consulted our hospital complaining of pain in the right side of her neck and upper right arm in August 1994.
  • Therefore, external beam radiotherapy (EBRT) combined with intra-arterial chemotherapy and hyperthermia was employed.
  • After the treatment, the tumor decreased in size to 45% of its initial volume, and, simultaneously, her symptoms completely disappeared.
  • The patient initially remained clinically free of the disease, but showed reaggravations at the primary tumor site 3 years and 3 months, and 4 years and 11 months, after the first treatment.
  • The reaggravations were treated with EBRT combined with intra-arterial chemotherapy.
  • As a result, she survived for 5 years and 7 months after the first treatment.
  • [MeSH-major] Head and Neck Neoplasms / diagnosis. Leiomyosarcoma / diagnosis. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Metastasis. Survivors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11942051.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


10. Sugiyama T, Hirose T, Hosaka T, Kusumoto S, Nakashima M, Yamaoka T, Okuda K, Ohmori T, Adachi M: Effectiveness of intensive follow-up after response in patients with small cell lung cancer. Lung Cancer; 2008 Feb;59(2):255-61
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated whether intensive follow-up leads to earlier diagnosis of recurrence, more effective treatment, and longer survival in patients with small cell lung cancer (SCLC) who had shown a complete or partial response to first-line chemotherapy.
  • The subjects of this retrospective study were 94 patients with SCLC who had shown a complete or partial response to first-line chemotherapy.
  • The patients were separated into two arms: an intensive follow-up arm in which patients underwent regular blood tests, chest radiography, computed tomography of the chest and upper abdomen, magnetic resonance or computed tomography of the brain, and bone scintigraphy bimonthly for 6 months and then quarterly for 1.5 years; and a nonintensive follow-up arm in which these examinations were performed at the physician's discretion.
  • Disease recurred in 55 of 62 patients of the intensive arm and 29 of 32 patients of the nonintensive arm.
  • Asymptomatic recurrences were detected more frequently in the intensive arm than in the nonintensive arm.
  • The response rate to salvage therapy among all patients with recurrent disease was significantly higher in the intensive arm (61.8%) than in the nonintensive arm (37.9%; p=0.04).
  • Both median postrelapse survival and overall median survival were significantly longer in the intensive arm (9 and 20 months, respectively, p=0.04 and p=0.001) than in the nonintensive arm (4 and 13 months, respectively).
  • Intensive follow-up helps detect recurrence earlier, enhances the effectiveness of treatment, and lengthens survival in patients with SCLC.
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Disease Progression. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Morbidity / trends. Neoplasm Recurrence, Local / epidemiology. Prognosis. Retrospective Studies. Survival Rate / trends. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lung Cancer. 2009 Jan;63(1):158 [18599151.001]
  • (PMID = 17900754.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


11. Kawamura J, Nagayama S, Nomura A, Itami A, Okabe H, Sato S, Watanabe G, Sakai Y: Long-term outcomes of peripheral arm ports implanted in patients with colorectal cancer. Int J Clin Oncol; 2008 Aug;13(4):349-54
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes of peripheral arm ports implanted in patients with colorectal cancer.
  • BACKGROUND: Venous ports are mandatory for chemotherapy in cancer patients because prolonged infusions are required.
  • The aim of this study was to assess the safety of peripheral arm ports for chemotherapy in patients with colorectal cancer.
  • METHODS: A peripheral venous access port was placed in the upper arm in 113 consecutive patients with metastatic colorectal cancer (MCRC).
  • RESULTS: Puncture of the basilic veins was successfully completed under real-time sonographic guidance or radiographic guidance in all patients.
  • The median operative time was 30 min.
  • One patient (0.9%) had an episode of ultrasound-documented deep vein thrombosis in the ipsilateral upper extremity (0.03/1000 catheter-days).
  • CONCLUSION: Peripheral arm ports can be maintained with excellent short-and long-term outcomes.
  • Peripheral arm ports are considered to be a good alternative to central venous ports implanted in the chest in patients with MCRC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Arm / blood supply. Catheterization, Peripheral. Catheters, Indwelling. Colorectal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Metastasis / drug therapy. Radiography, Interventional. Ultrasonography, Interventional

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Clin Oncol. 2010 Jun;15(3):328-30 [20195679.001]
  • [Cites] Cancer. 2007 Nov 15;110(10):2331-8 [17886248.001]
  • [Cites] Bone Marrow Transplant. 1999 Jul;24(1):89-93 [10435741.001]
  • [Cites] Gynecol Oncol. 1996 Mar;60(3):397-9 [8774645.001]
  • [Cites] Radiology. 1992 Jul;184(1):149-51 [1609072.001]
  • [Cites] J Vasc Interv Radiol. 1997 Nov-Dec;8(6):991-5 [9399468.001]
  • [Cites] Radiology. 1998 Feb;206(2):423-8 [9457195.001]
  • [Cites] Ann Oncol. 2008 Jan;19(1):9-15 [17846025.001]
  • [Cites] Cardiovasc Intervent Radiol. 2000 May-Jun;23(3):187-93 [10821892.001]
  • [Cites] Gynecol Oncol. 1996 Sep;62(3):340-3 [8812530.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4553-60 [16002847.001]
  • [Cites] Rofo. 1997 Mar;166(3):230-2 [9156594.001]
  • [Cites] Can Assoc Radiol J. 2000 Jun;51(3):163-9 [10914081.001]
  • [Cites] AJR Am J Roentgenol. 1997 Nov;169(5):1431-4 [9353475.001]
  • [Cites] Cardiovasc Intervent Radiol. 2001 May-Jun;24(3):180-4 [11443406.001]
  • [Cites] Ann Fr Anesth Reanim. 2000 Mar;19(3):171-6 [10782240.001]
  • [Cites] Radiology. 1990 Nov;177(2):353-6 [2217768.001]
  • [Cites] AJR Am J Roentgenol. 1998 Jun;170(6):1613-6 [9609183.001]
  • [Cites] Radiology. 1996 Dec;201(3):725-30 [8939222.001]
  • [Cites] J Surg Oncol. 1996 Jul;62(3):222-5 [8667632.001]
  • [Cites] J Vasc Interv Radiol. 2002 Feb;13(2 Pt 1):179-84 [11830624.001]
  • [Cites] AJR Am J Roentgenol. 1997 May;168(5):1235-9 [9129419.001]
  • [Cites] World J Surg. 1998 Jan;22(1):12-6 [9465755.001]
  • [Cites] Am Surg. 2004 Jul;70(7):635-44 [15279190.001]
  • [Cites] Arch Surg. 2001 Sep;136(9):1050-3 [11529829.001]
  • [Cites] Cardiovasc Intervent Radiol. 1998 May-Jun;21(3):230-3 [9626440.001]
  • (PMID = 18704637.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


12. Wasner G, Hilpert F, Schattschneider J, Binder A, Pfisterer J, Baron R: Docetaxel-induced nail changes--a neurogenic mechanism: a case report. J Neurooncol; 2002 Jun;58(2):167-74
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Docetaxel is a new taxoid widely used in chemotherapy for advanced breast cancer and other solid malignancies.
  • We report a patient with a complete peripheral palsy of the right arm due to advanced breast cancer with diffuse tumor infiltration of the brachial plexus.
  • Treatment with docetaxel led to onycholysis at all extremities except the paretic hand.
  • Sensory and motoric innervation measured by nerve conduction studies showed a complete loss of large nerve fiber function of the right arm.
  • In summary, a severe denervation of small and large fibers of the right upper limb was revealed.
  • [MeSH-major] Arm. Breast Neoplasms / complications. Breast Neoplasms / drug therapy. Nail Diseases / chemically induced. Paclitaxel / adverse effects. Paclitaxel / analogs & derivatives. Paralysis / etiology. Taxoids
  • [MeSH-minor] Afferent Pathways / physiopathology. Brachial Plexus / pathology. Efferent Pathways / physiopathology. Female. Humans. Middle Aged. Motor Neurons / physiology. Neoplasm Invasiveness. Neural Conduction. Neurologic Examination. Neurons, Afferent / physiology. Parasympathetic Nervous System / physiopathology. Sensory Thresholds. Skin / innervation. Sympathetic Nervous System / physiopathology. Vibration

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Nail Diseases.
  • MedlinePlus Health Information. consumer health - Paralysis.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Physiol. 1980 Sep;306:537-52 [7463376.001]
  • [Cites] Science. 1990 Apr 20;248(4953):370-2 [1970196.001]
  • [Cites] Semin Oncol. 1995 Dec;22(6 Suppl 13):17-21 [8604448.001]
  • [Cites] Lancet. 2000 Aug 5;356(9228):507-8 [10981914.001]
  • [Cites] Mayo Clin Proc. 1983 Sep;58(9):583-92 [6310277.001]
  • [Cites] Pain. 1996 Oct;67(2-3):317-26 [8951925.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1672-8 [8622087.001]
  • [Cites] Dermatology. 1999;198(3):288-90 [10393455.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3149-55 [9294478.001]
  • [Cites] J Neurol. 2000 Apr;247(4):267-72 [10836618.001]
  • [Cites] Lancet. 2001 Mar 24;357(9260):910 [11289346.001]
  • [Cites] Diabet Med. 1992 Mar;9(2):166-75 [1563252.001]
  • [Cites] J Leukoc Biol. 1992 Jul;52(1):119-21 [1353517.001]
  • [Cites] Ann Oncol. 1994 Jul;5(6):527-32 [7918124.001]
  • [Cites] Neuroscience. 1995 Mar;65(1):283-91 [7753402.001]
  • [Cites] Neuroscience. 1997 Nov;81(1):255-62 [9300418.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1976 Nov;39(11):1071-5 [188989.001]
  • [Cites] Cancer. 2000 May 15;88(10):2367-71 [10820360.001]
  • [Cites] Ann Oncol. 1998 Feb;9(2):230-1 [9553674.001]
  • [Cites] Brain. 1991 Aug;114 ( Pt 4):1819-26 [1884180.001]
  • [Cites] Ann Pharmacother. 1999 May;33(5):584-6 [10369623.001]
  • [Cites] J Auton Nerv Syst. 1996 Sep 12;60(3):147-53 [8912264.001]
  • [Cites] Brain. 1993 Dec;116 ( Pt 6):1477-96 [8293282.001]
  • [Cites] Bibl Anat. 1965;7:314-24 [5860752.001]
  • [Cites] Muscle Nerve. 1993 Jul;16(7):757-68 [8505932.001]
  • [Cites] Muscle Nerve. 1992 Apr;15(4):507-12 [1565120.001]
  • [Cites] Ann Oncol. 1993 Aug;4(7):610-1 [8103352.001]
  • [Cites] J Am Acad Dermatol. 1984 Feb;10(2 Pt 1):250-8 [6371069.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1991 Nov;54(11):965-71 [1800668.001]
  • [Cites] J Neurosci. 1997 May 1;17(9):3234-8 [9157197.001]
  • [Cites] Rev Physiol Biochem Pharmacol. 1992;121:49-146 [1485073.001]
  • [Cites] Lancet. 2000 Apr 1;355(9210):1176-8 [10791395.001]
  • [Cites] J Physiol. 1992 Mar;448:749-64 [1593488.001]
  • [Cites] Arch Dermatol. 1998 Sep;134(9):1167-8 [9762045.001]
  • (PMID = 12164689.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


13. Shah MA, Schwartz GK: Treatment of metastatic esophagus and gastric cancer. Semin Oncol; 2004 Aug;31(4):574-87
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of metastatic esophagus and gastric cancer.
  • Cancers of the upper gastrointestinal tract include cancers of the esophagus, gastroesophageal junction, and stomach.
  • Metastatic or unresectable upper gastrointestinal malignancies are incurable but do benefit from palliative chemotherapy.
  • Several agents have been examined in the treatment of these diseases, with modest single-agent activity.
  • Several combination therapies have been developed and have been examined in recent large phase III randomized clinical trials.
  • These studies, for the most part, have failed to demonstrate a survival advantage over the reference arm.
  • However, with the examination of newer cytotoxic agents, as well as with the application of molecularly targeted approaches to upper gastrointestinal malignancies, there remains hope for improved therapies for these diseases in the future.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Esophageal Neoplasms / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Clinical Trials as Topic. Humans. Neoplasm Metastasis. Palliative Care


14. Chughtai A, Cronin P, Lucas DR, Prager R, Kazerooni EA: Metastatic shoulder liposarcoma to the right ventricle: CT findings. J Thorac Imaging; 2007 May;22(2):195-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A right ventricular liposarcoma metastasis is described in a 46-year-old man, who was admitted with significant shortness of breath and fatigue, and in whom a large lobulated low attenuation mass occupying most of the right ventricular cavity, with extension through the right ventricular apex and a small-to-moderate pericardial effusion was detected by electrocardiogram-gated cardiac computed tomography.
  • The patient had an antecedent history of a left upper arm liposarcoma treated with surgical resection, chemotherapy, and postoperative radiotherapy 3 years earlier.
  • Surgical resection was performed with the majority of the neoplasm removed though; the right ventricular apex and epicardial extension of tumor could not be fully resected.
  • The histopathologic analysis revealed a liposarcoma, similar to the one resected in the left arm 3 years earlier.
  • Electrocardiogram-gated cardiac computed tomography was able to visualize the metastatic tumor within the heart, accurately evaluate cardiac function and allow for prompt surgical treatment that produced relief of symptoms, and assess for further metastatic disease within the thorax.
  • [MeSH-major] Bone Neoplasms / pathology. Heart Neoplasms / diagnosis. Heart Neoplasms / secondary. Liposarcoma / diagnosis. Shoulder / pathology. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Liposarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17527130.001).
  • [ISSN] 0883-5993
  • [Journal-full-title] Journal of thoracic imaging
  • [ISO-abbreviation] J Thorac Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 4419T9MX03 / Iohexol
  •  go-up   go-down


15. Post IC, van Ingen G, Hendriks TR, Plaisier PW: [A 73-year-old man with a Merkel cell carcinoma]. Ned Tijdschr Geneeskd; 2010;154:A1974
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 73-year-old man had a firm node on his right upper arm, which was caused by a Merkel cell carcinoma (MCC).
  • During a CT scan of the thorax and abdomen, 2 suspicious abnormalities were seen in the mesenterial adipose tissue of the left lower abdomen and left perirenal adipose tissue.
  • A tissue sample of the last abnormality taken under CT guidance confirmed this to be a metastasis of the MCC.
  • The patient was irradiated but chose not to have chemotherapy.
  • Merkel cell carcinoma is a rare and aggressive malignant skin neoplasm.
  • Treatment is multidisciplinary, but surgery, either alone or in combination with radiotherapy, forms the basis of treating both the localised and regionalized forms of the disease.
  • Chemotherapy may be used in case of disseminated disease and has a reasonable, albeit temporary, effect.
  • [MeSH-major] Carcinoma, Merkel Cell / diagnosis. Neoplasms, Adipose Tissue / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Fatal Outcome. Humans. Male. Neoplasm Metastasis. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21029484.001).
  • [ISSN] 1876-8784
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


16. Murray PM: Soft tissue sarcoma of the upper extremity. Hand Clin; 2004 Aug;20(3):325-33, vii
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue sarcoma of the upper extremity.
  • Soft tissue sarcomas of the upper extremities are rare and hand surgeons typically encounter only one or two undiagnosed soft tissue sarcomas during their careers.
  • It is incumbent on the physician to review repeatedly the characteristics of these tumors and remain suspicious, because these lesions typically are misdiagnosed and treatment is delayed.
  • The most common soft tissue sarcomas of the upper extremity are the epithelioid sarcoma, synovial cell sarcoma, and malignant fibrous histiocytoma.
  • Limb salvage surgery is the treatment of choice for soft tissue sarcomas to preserve upper extremity function.
  • Following wide tumor resection, adjuvant therapies such as chemotherapy, external beam radiation therapy, and brachytherapy may lessen local recurrence rates, but their effect on overall survival remains unclear.
  • [MeSH-major] Sarcoma. Soft Tissue Neoplasms
  • [MeSH-minor] Arm. Biopsy. Chemotherapy, Adjuvant. Dermatofibrosarcoma / diagnosis. Dermatofibrosarcoma / surgery. Fibrosarcoma / pathology. Fibrosarcoma / therapy. Histiocytoma, Benign Fibrous / mortality. Histiocytoma, Benign Fibrous / pathology. Humans. Liposarcoma / pathology. Neoplasm Metastasis. Neoplasm Recurrence, Local. Prognosis. Rhabdomyosarcoma / pathology. Rhabdomyosarcoma / therapy. Sarcoma, Clear Cell / diagnosis. Sarcoma, Synovial / diagnosis

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15275691.001).
  • [ISSN] 0749-0712
  • [Journal-full-title] Hand clinics
  • [ISO-abbreviation] Hand Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 46
  •  go-up   go-down


17. Chibaudel B, Tournigand C, Artru P, André T, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Rivera F, Perez-Staub N, Louvet C, de Gramont A: FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 study. Ann Oncol; 2009 Aug;20(8):1383-6
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with ALP more than three times the upper limit of normal (ULN) were excluded from our previous studies evaluating chemotherapy.
  • PATIENTS AND METHODS: Previously untreated patients with MCRC were randomized to FOLFOX4 until progression (arm A) or FOLFOX7 for six cycles, maintenance without oxaliplatin for 12 cycles and reintroduction of FOLFOX7 (arm B).
  • RESULTS: Among the 620 patients in OPTIMOX1 study, 63 had ALP 3-5 ULN; 33 in arm A and 30 in arm B.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19465426.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; EC 3.1.3.1 / Alkaline Phosphatase; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


18. Oei AL, Massuger LF, Oyen WJ: Extraperitoneal leakage as a possible explanation for failure of one-time intraperitoneal treatment in ovarian cancer. Cancer Biother Radiopharm; 2007 Aug;22(4):508-14
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraperitoneal leakage as a possible explanation for failure of one-time intraperitoneal treatment in ovarian cancer.
  • We conducted a single-arm study to determine the biodistribution of intraperitoneally (i.p.) administered 90yttrium-labeled murine monoclonal antibody HMFG1 (90Y-muHMFG1) in patients with advanced stage ovarian cancer.
  • After completion of chemotherapy, a mixture of 111indium-labeled muHMFG1 (imaging) and 90Y-muHMFG1 (therapy) was i.p. administered by a surgically placed, indwelling i.p. catheter.
  • Planar and single-photon emission computed tomography images were recorded to determine the distribution of the study medication during the first 6 days postinjection.
  • Of the first 3 patients, 2 patients had extraperitoneal leakage of up to 50% of the injected dose within 24 hours after injection of the study medication.
  • Extraperitoneal leakage was mainly seen in the retroperitoneal spaces covering the upper and lower quadrant of the abdomen.
  • After adjustments in the procedure, leakage was observed in 2 of the remaining 14 patients.
  • Extraperitoneal leakage of i.p. administered therapy does occur.
  • Such leakage would reduce the locally delivered dose of a drug and could potentially have a negative impact on therapeutic efficacy.
  • Given the potential attraction of developing i.p. treatments for intra-abdominal cancer, the observations in this study need to be taken into consideration.
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / chemistry. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / therapeutic use. Female. Humans. Injections, Intraperitoneal. Neoplasm Staging. Radioimmunotherapy. Time Factors. Treatment Failure. Yttrium Radioisotopes / chemistry. Yttrium Radioisotopes / therapeutic use

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17803445.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Yttrium Radioisotopes; 0 / pemtumomab
  •  go-up   go-down


19. Torigoe T, Yazawa Y, Takagi T, Terakado A, Kurosawa H: Extraskeletal osteosarcoma in Japan: multiinstitutional study of 20 patients from the Japanese Musculoskeletal Oncology Group. J Orthop Sci; 2007 Sep;12(5):424-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Unlike osteosarcoma of the bone, the efficacy of chemotherapy for extraskeletal osteosarcoma has not been established yet.
  • Six lesions were located in the thigh, four in the chest, four in the buttocks, three in the upper arm, and others.
  • Altogether, 15 patients received chemotherapy, of whom 11 had evaluable responses as follows: complete response in none, partial response in 5 patients, and no change or progressive disease in 6 patients, with a response rate of 45%.
  • CONCLUSIONS: Among the patients with extraskeletal osteosarcoma, both the 5-year survival rate and the chemotherapy response rate tended to improve in this study in comparison to the findings published in previous reports.
  • As a result, we believe that treatment regimens that include systemic chemotherapy may be able to improve the prognosis in patients with extraskeletal osteosarcoma.
  • [MeSH-major] Osteosarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Japan / epidemiology. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17909926.001).
  • [ISSN] 0949-2658
  • [Journal-full-title] Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  • [ISO-abbreviation] J Orthop Sci
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Japan
  •  go-up   go-down


20. Grünhagen DJ, de Wilt JH, Verhoef C, van Geel AN, Eggermont AM: TNF-based isolated limb perfusion in unresectable extremity desmoid tumours. Eur J Surg Oncol; 2005 Oct;31(8):912-6
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Desmoid tumours are soft tissue sarcomas with local aggressive behaviour and a high rate of local recurrence after treatment.
  • As isolated limb perfusion (ILP) with TNF and melphalan has proven to be extremely effective in the treatment of soft tissue sarcoma, we studied its potential in locally advanced extremity desmoid tumours.
  • Local surgical therapy with preservation of limb function was impossible in all patients due to large or multifocal tumours, multiple recurrences or extensive previous treatment.
  • Perfusions were performed with 4-3mg TNF and 10-13 mg/l limb volume melphalan form leg and arm perfusions, respectively.
  • Local control was obtained after 10/12 ILPs and in the other two patients through repeat ILP and systemic chemotherapy, thus leading to an overall local control rate of 100%.
  • CONCLUSION: ILP is a very effective treatment option in the multimodality treatment of limb desmoid tumours.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Chemotherapy, Cancer, Regional Perfusion. Dermoid Cyst / drug therapy. Lower Extremity / pathology. Melphalan / administration & dosage. Soft Tissue Neoplasms / drug therapy. Tumor Necrosis Factor-alpha / administration & dosage. Upper Extremity / pathology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease Progression. Female. Humans. Limb Salvage. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Prospective Studies. Remission Induction. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16098709.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down


21. Yoshida T, Horiguchi J, Koibuchi Y, Kanoh T, Iijima K, Yoshida M, Kikuchi M, Takata D, Oyama T, Iino Y, Morishita Y: [Metastatic breast cancer treated with trastuzumab and paclitaxel--a case report with clinically complete response]. Gan To Kagaku Ryoho; 2004 Jun;31(6):907-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After surgery, treatment of UFT and CPA was started.
  • Seven months after surgery, metastasis occurred at the left supraclavicular lymph node, and CPA, THP-adriamycine and 5-FU therapy was started.
  • Fourteen months after surgery, skin redness of the left upper arm, the left chest wall and contralateral breast, and a contralateral axillary lymph node swelling were recognized.
  • Neither docetaxel nor mitoxantrone-combined therapy was effective.
  • Trastuzumab therapy was started because of HER2 overexpression by immunohistochemistry, and partial response was received after 7 weeks.
  • Four months later, multiple nodules in the chest wall were recognized, and weekly treatment of trastuzumab and paclitaxel was started.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Lymphatic Metastasis. Middle Aged. Paclitaxel / administration & dosage. Receptor, ErbB-2 / biosynthesis. Remission Induction. Trastuzumab

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15222110.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


22. Twelves CJ: Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness. Clin Colorectal Cancer; 2006 Nov;6(4):278-87
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness.
  • The X-ACT (Xeloda in Adjuvant Colon Cancer Therapy) trial compared the efficacy and safety of the oral fluoropyrimidine capecitabine with bolus 5-fluorouracil (5-FU)/leucovorin (LV; Mayo Clinic regimen) as adjuvant therapy for stage III colon cancer.
  • Disease-free survival (primary study endpoint) in the capecitabine arm was at least equivalent to that in the 5-FU/LV arm; the upper limit of the hazard ratio was significantly (P < 0.001) below the predefined margins for noninferiority.
  • Pharmacoeconomic analyses performed in several countries show that the savings in direct costs (drug administration and AE-related costs) associated with capecitabine versus 5-FU/LV offset the acquisition costs of the drug.
  • Furthermore, capecitabine reduces patient travel time and costs, making it a "dominant" strategy (ie, less costly and more effective) in the adjuvant setting.
  • In conclusion, efficacy, safety, convenience, and cost findings from the X-ACT trial show that capecitabine offers at least equivalent clinical benefit compared with bolus 5-FU/LV and can replace intravenous 5-FU/LV in the adjuvant treatment of stage III colon cancer.
  • The X-ACT trial has not only helped to better define the role of capecitabine but has also broadened the options available to patients with early-stage disease to include a uniquely effective oral outpatient treatment.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Colonic Neoplasms / drug therapy. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives
  • [MeSH-minor] Capecitabine. Clinical Trials as Topic. Cost-Benefit Analysis. Humans. Leucovorin / administration & dosage. Neoplasm Staging

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17241512.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Number-of-references] 48
  •  go-up   go-down


23. Nishimura T, Sanada J, Furukawa M: Cervical radiculopathy due to intra-arterial infusion of cisplatin. J Laryngol Otol; 2005 Aug;119(8):649-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three hours after the CDDP infusion, he had noticed general weakness of the left upper extremity and hypoaesthesia of the lateral side of the upper and lower arm.
  • This procedure should be carefully indicated in the case of a large neck tumour that is perfused from the major branches of the subclavian artery.
  • [MeSH-minor] Humans. Infusions, Intra-Arterial / adverse effects. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiography. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiography. Subclavian Artery / radiography. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16102225.001).
  • [ISSN] 0022-2151
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 4
  •  go-up   go-down


24. Zatloukal P, Cardenal F, Szczesna A, Gorbunova V, Moiseyenko V, Zhang X, Cisar L, Soria JC, Domine M, Thomas M: A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol; 2010 Sep;21(9):1810-6
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Noninferiority of IP versus EP was established, upper bound of the 95% CI of HR 1.01 (prespecified margin IP/EP <1.25).
  • Overall response (39.1% versus 46.6%) and time to tumor progression (5.4 versus 6.2 months) were not superior for IP.
  • Grade 3/4 vomiting (10.9% versus 4.4%) and diarrhea (15.4% versus 0.5%) were more common in the IP versus EP arm; grade 3/4 neutropenia was more frequent in the EP (59.6%) versus IP arm (38.1%).

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20231298.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


25. Altmann S, Lenz-Scharf O, Schneider W: [Therapeutic options for aggressive fibromatosis]. Handchir Mikrochir Plast Chir; 2008 Apr;40(2):88-93
Genetic Alliance. consumer health - Fibromatosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic options for aggressive fibromatosis].
  • INTRODUCTION: Aggressive fibromatosis, e.g., desmoid tumour, is a rare neoplasm of the connective tissue with local infiltrative growth.
  • Because of the high recurrence rates and destruction of the surrounding tissue, these tumours are classified as semi-malignant.
  • Radical surgical treatment with tumour excision accompanied by radiotherapy is the current standard therapy that can be supplemented by pharmacological treatment in a few cases.
  • PATIENTS AND METHOD: We report on 9 patients (5 males and 4 females) with surgical therapy for aggressive fibromatosis.
  • The neoplasm was located on the extremities in 7 cases (4 x upper extremity, 3 x lower extremity), one tumour was situated in the chin and one in the rectus abdominis muscle.
  • In these cases, an adjuvant radiotherapy with 25 x 2 Gy was started postoperatively after the accomplished wound healing.
  • Treatment with chemotherapeutic agents was not necessary.
  • DISCUSSION: Aggressive fibromatosis is a semimalignant neoplasm of the connective tissue with an extremely high recurrence rate.
  • Therapy of choice is the radical surgical resection.
  • Pharmacological treatment should be considered for patients with unsuccessful local therapy.
  • [MeSH-major] Fibromatosis, Aggressive / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adult. Arm. Chin. Female. Follow-Up Studies. Humans. Leg. Magnetic Resonance Imaging. Male. Middle Aged. Postoperative Care. Radiotherapy Dosage. Radiotherapy, Adjuvant. Rectus Abdominis. Surgical Flaps. Time Factors

  • Genetic Alliance. consumer health - Aggressive Fibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18437666.001).
  • [ISSN] 0722-1819
  • [Journal-full-title] Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft für Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft für Mikrochirurgie der Peripheren Nerven und Gefässe : Organ der Vereinigung der Deutschen Plastischen Chirurgen
  • [ISO-abbreviation] Handchir Mikrochir Plast Chir
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


26. Halimi JM, Azizi M, Bobrie G, Bouché O, Deray G, des Guetz G, Lecomte T, Levy B, Mourad JJ, Nochy D, Oudard S, Rieu P, Sahali D: [Vascular and renal effects of anti-angiogenic therapy]. Nephrol Ther; 2008 Dec;4(7):602-15
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Vascular and renal effects of anti-angiogenic therapy].
  • [Transliterated title] Effets vasculaires et rénaux des médicaments anti-angiogéniques: recommandations françaises pour la pratique (SN, SFHTA, APNET, FFCD).
  • Angiogenesis inhibitor drugs (bevacizumab, sunitinib, sorafénib...) are now widely used for treatment of cancers, including colorectal, advanced renal cell and hepatocellular carcinomas, breast cancer).
  • Vascular and renal side-effects of these drugs are not well known.
  • Arterial pressure can usually be controlled with anti-hypertensive medications, and treatment with angiogenesis inhibitors can be continued in most cases; however, serious hypertension-induced side effects were reported included malignant hypertension, stroke and reversible posterior leucoencephalopathy.
  • (1) before the first administration of angiogenesis inhibitors: acute IV or oral antihypertensive medications should not be administered in a patient regardless of arterial pressure levels with postponing the administration because of hypertension is not recommended;.
  • (2) initial work-up should include ambulatory measurement of arterial pressure (by the general practitioner or by the patient using home blood pressure (three times in the morning and in the evening during three consecutive days) with a validated (cf: http://afssaps.sante.fr/) upper arm device: ideally, this device should be financed and provided by the pharmaceutical companies marketing the angiogenesis inhibitor drugs.
  • (3) urine dipstick (and quantification if positive) and estimated glomerular filtration rate (using abbreviated MDRD rather than Cockcroft-Gault formula) must be performed before treatment and regularly during follow-up;.
  • (4) therapeutic management must be done in accordance with national or international guidelines (in France: http://www.has-sante.fr/);.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Colorectal Neoplasms / drug therapy. Kidney / pathology
  • [MeSH-minor] Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Benzenesulfonates / adverse effects. Benzenesulfonates / therapeutic use. Bevacizumab. Glomerular Filtration Rate / drug effects. Glomerulonephritis / chemically induced. Humans. Indoles / adverse effects. Indoles / therapeutic use. Neoplasm Metastasis / drug therapy. Niacinamide / analogs & derivatives. Phenylurea Compounds. Practice Guidelines as Topic. Proteinuria / chemically induced. Pyridines / adverse effects. Pyridines / therapeutic use. Pyrroles / adverse effects. Pyrroles / therapeutic use. Vascular Endothelial Growth Factor A / drug effects. Vascular Endothelial Growth Factor A / physiology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19027389.001).
  • [ISSN] 1769-7255
  • [Journal-full-title] Néphrologie & thérapeutique
  • [ISO-abbreviation] Nephrol. Ther.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Indoles; 0 / Phenylurea Compounds; 0 / Pyridines; 0 / Pyrroles; 0 / Vascular Endothelial Growth Factor A; 0 / sunitinib; 25X51I8RD4 / Niacinamide; 2S9ZZM9Q9V / Bevacizumab; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


27. Keller SM, Vangel MG, Wagner H, Schiller J, Herskovic A, Komaki R, Gray R, Marks RS, Perry MC, Livingston RB, Johnson DH, Eastern Cooperative Oncology Group: Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer. Lung Cancer; 2003 Oct;42(1):79-86
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer.
  • The occurrence of second primary tumors (SPTs) following adjuvant therapy for resected stages II and IIIa non-small cell lung cancer (NSCLC) was investigated.
  • Data regarding SPTs were prospectively collected in all patients accrued to Eastern Cooperative Group Oncology E3590 (a phase III trial of adjuvant therapy in patients with completely resected stages II and IIIa NSCLC).
  • Four hundred eighty-eight patients were accrued to the study, 242 to the RT arm and 246 to the CRT arm.
  • Thirty patients (6.1%) developed 33 SPTs, 20 in the RT arm and ten in the CRT arm.
  • Ten SPTs occurred within the upper aerodigestive tract, six in the RT arm and four in the CRT arm.
  • Twenty-three SPTs occurred in other organs, 17 in the RT arm and six in the CRT arm.
  • Median time to detection of a SPT for those patients randomized to RT and CRT was 43 and 36 months, respectively.
  • Excluding skin tumors, the relative risk of death following diagnosis of a SPT for patients randomized to the CRT arm as compared with those randomized to RT alone was 2.26 (95% confidence interval, 0.78-5.58, P=0.12).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / therapy. Lung Neoplasms / therapy. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Radiotherapy, Adjuvant. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14512191.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA14958; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / CA21076; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / CA21661; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / CA25224; United States / NCI NIH HHS / CA / CA49957; United States / NCI NIH HHS / CA / CA66636; United States / NCI NIH HHS / CA / CA73590
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Ireland
  •  go-up   go-down


28. Chertin B, Spitz IM, Lindenberg T, Algur N, Zer T, Kuzma P, Young AJ, Catane R, Farkas A: An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer. J Urol; 2000 Mar;163(3):838-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: The 2.6 cm. implant releasing 60 microg. histrelin daily is inserted subcutaneously into the upper arm using local anesthesia.
  • Treatment with the antiandrogen flutamide or cyproterone acetate began 2 weeks before implant insertion and continued for up to 12 weeks.
  • Prostate specific antigen began to decrease during antiandrogen therapy and decreased further after implant insertion.
  • Duration of treatment in the remaining 9 patients was between 21 and 30 months.
  • [MeSH-major] Androgen Antagonists / therapeutic use. Gonadotropin-Releasing Hormone / analogs & derivatives. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Drug Implants. Humans. Male. Middle Aged. Neoplasm Metastasis. Time Factors

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. HISTRELIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10687989.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Drug Implants; 33515-09-2 / Gonadotropin-Releasing Hormone; H50H3S3W74 / histrelin
  •  go-up   go-down


29. Ball C, Thomson KR, Kavnoudias H: Irreversible electroporation: a new challenge in "out of operating theater" anesthesia. Anesth Analg; 2010 May 1;110(5):1305-9
Hazardous Substances Data Bank. Isoflurane .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A clinical trial of IRE as a tumor ablation therapy was performed at our institution.
  • A pulsating direct current of 20 to 50 A and 500 to 3000 V was delivered into metastatic or primary tumors in the liver, kidney, or lung via needle electrodes inserted under computed tomography (CT) or ultrasound guidance.
  • The electrical discharge produced generalized upper body muscular contractions requiring neuromuscular blockade.
  • Two patients developed positional neuropraxia because of the extended arm position requested for CT scanning.
  • After experimentation, we have developed a modified arm position.
  • Some patients developed self-limiting ventricular tachycardias that are now minimized by using an electrocardiogram synchronizer.
  • Three patients developed pneumothoraces as a result of the needle electrode insertion.
  • [MeSH-major] Electroporation / methods. Neoplasms / therapy
  • [MeSH-minor] Acid-Base Imbalance / etiology. Adult. Aged. Aged, 80 and over. Anesthesia, General. Anesthetics, Inhalation. Anesthetics, Intravenous. Arrhythmias, Cardiac / etiology. Electrocardiography. Electrodes. Electroencephalography / drug effects. Female. Humans. Hypertension / etiology. Isoflurane. Male. Middle Aged. Muscle, Skeletal / physiology. Neoplasm Metastasis / therapy. Pain, Postoperative / epidemiology. Pneumothorax / etiology. Propofol. Tomography, X-Ray Computed. Water-Electrolyte Imbalance / etiology

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. PROPOFOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Anesth Analg. 2010 May 1;110(5):1264 [20418290.001]
  • (PMID = 20142349.001).
  • [ISSN] 1526-7598
  • [Journal-full-title] Anesthesia and analgesia
  • [ISO-abbreviation] Anesth. Analg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anesthetics, Inhalation; 0 / Anesthetics, Intravenous; CYS9AKD70P / Isoflurane; YI7VU623SF / Propofol
  •  go-up   go-down






Advertisement